ArticleActa oncologica (Stockholm, Sweden)2025

Pembrolizumab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a multi-institutional DAHANCA cohort study.

Sebastian Søby et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.